Stocks · News reference

Compugen Q1 2026 Earnings Call: Complete Transcript

Jun 1, 2026, 1:04 PMBenzinga Insights

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Keep reading

BenzingaAug 3, 2026, 11:01 AMBenzinga Newsdesk
Compugen Q2 EPS $(0.07), Inline, Sales $2.602M Beat $1.606M Estimate
Compugen (NASDAQ:CGEN) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 12.5 percent increase over losses of $(0.08) per share from the same period last year. The
Read original at benzinga
CGEN
BenzingaJun 18, 2026, 11:12 AMBenzinga Newsdesk
Compugen Presents Trial-In-Progress Poster On MAIA-Ovarian Adaptive Platform Trial Of COM701, Potential Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Read original at benzinga
CGEN
BenzingaJun 11, 2026, 11:14 AMBenzinga Newsdesk
Compugen To Present Trial-In-Progress Poster On MAIA-Ovarian Phase 1 Study Of COM701, Anti-PVRIG Antibody, At ESMO Gynaecological Cancers Congress 2026
Compugen Ltd. (NASDAQ:CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in predictive computational drug target discovery powered by AI/ML, today announced that it will present a
Read original at benzinga
CGEN